Frederick Locke, MD

    Frederick Locke, MD

    Coleader of the Immunology Program, Moffitt Cancer Center
    • Are CAR T-Cell Therapies Worth the Costs? Saturday, February 1st, 2020

      Since the first chimeric antigen receptor (CAR) T-cell therapies gained FDA approval in 2017, the one-time treatments have led to unprecedented response rates in patients with diffuse large B cell lymphoma (DLBCL) and B-cell acute lymphocytic leukemia (ALL). Of course, they also came with unprecedented price tags: List prices for tisagenlecleucel and axicabtagene ciloleucel are [...]